Works matching IS 11707690 AND DT 2022 AND VI 40 AND IP 12
Results: 10
Response to Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia".
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1265, doi. 10.1007/s40273-022-01213-y
- By:
- Publication type:
- Article
Economic Implications of Endometriosis: A Review.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1143, doi. 10.1007/s40273-022-01211-0
- By:
- Publication type:
- Article
Comment on "An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia".
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1261, doi. 10.1007/s40273-022-01200-3
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1247, doi. 10.1007/s40273-022-01196-w
- By:
- Publication type:
- Article
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1131, doi. 10.1007/s40273-022-01195-x
- By:
- Publication type:
- Article
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1221, doi. 10.1007/s40273-022-01194-y
- By:
- Publication type:
- Article
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1207, doi. 10.1007/s40273-022-01191-1
- By:
- Publication type:
- Article
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1159, doi. 10.1007/s40273-022-01189-9
- By:
- Publication type:
- Article
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1187, doi. 10.1007/s40273-022-01182-2
- By:
- Publication type:
- Article